Please login to the form below

DMD

This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Sarepta’s new Duchenne drug over safety fears

These patients represent around 8% of the DMD population, while those with the exon 51 mutation account for around 13%. ... The company is also investing in gene therapies for DMD and a range of other rare diseases as well as multiple sclerosis.

Latest news

Sarepta investigating mistakenly submitted Duchenne therapy report

rhabdomyolysis. This is a serious condition which is a commonly understood risk associated with DMD and can lead to complications such as kidney failure. ... Sarepta has been the lead in the DMD market, with some studies of its approved gene therapy
Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial. Data from a trial of Pfizer’s gene therapy for Duchenne muscular dystrophy (DMD) have shown signs of efficacy, but also safety concerns ... Typically children with DMD would have stable NSAA scores or see a
Vertex eyes Duchenne market with Exonics, CRISPR deals

First up is a deal to acquire US biotech Exonics Therapeutics, which is developing gene-editing therapies for DMD and other genetic neuromuscular diseases including myotonic dystrophy type 1 (DM1). ... That deal also focuses on gene-editing technology
Ex-Pharmacyclics CEO invests $25m in Summit

It’s also a boost to the UK company after the disappointment of its recent failed programme in Duchenne muscular dystrophy (DMD), which prompted its re-focusing as an anti-infectives
Entering the era of digital trials

A version of the phenomenon affects trials in muscle disorders such as Duchenne muscular dystrophy (DMD). ... One study found kids with DMD walked 11% further if they were offered $50 (£39) to beat their previous distance.

More from news
Approximately 9 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Tackling a formidable foe

Like other DMDs, metal exposure should be avoided,” adds Ben- Amor, who has been involved in MS research and business operations for 20 years.
Pharma deals during November 2014

additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00. Prosensa has been busy since drisapersen failed a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Catabasis hires Rick Modi as its chief business officer

We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Solaris Health looks at the gene therapy revolution

for instance to treat haemophilia, rare ophthalmic disorders and for Duchenne muscular dystrophy/DMD), genetic therapies are likely to represent a revolution in medicine over the coming years. ... However, in most areas where genetic treatments are being

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Competitive salary plus benefits

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Client Services Director- Flexible Working: Negotiable

Account Manager – Healthcare advertising: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...